Overall, NF-κB is crucial to the pathogenesis of BD, and inhibiting the NF-κB signaling pathway or using miRNA-targeted therapy may be effective ways to reduce the inflammatory response in BD (65). This evidence concerns the gene NFKB1 and Behcet disease.